Fulgent Genetics (FLGT) Expected to Announce Quarterly Earnings on Thursday

Fulgent Genetics (NASDAQ:FLGT) is anticipated to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Fulgent Genetics to post earnings of ($0.65) per share and revenue of $86.30 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Fulgent Genetics (NASDAQ:FLGT) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.12). Fulgent Genetics had a negative net margin of 26.05% and a negative return on equity of 4.93%. The business had revenue of $85.39 million during the quarter, compared to analyst estimates of $94.00 million. On average, analysts expect Fulgent Genetics to post ($3.48) EPS for the current fiscal year and ($2.76) EPS for the next fiscal year.

Fulgent Genetics Price Performance

Shares of NASDAQ:FLGT opened at $21.52 on Thursday. The company’s 50-day moving average price is $20.72 and its two-hundred day moving average price is $19.58. Fulgent Genetics has a one year low of $13.46 and a one year high of $31.04. The stock has a market capitalization of $592.12 million, a PE ratio of -7.63 and a beta of 0.93.

Analyst Ratings Changes

Several equities analysts have recently weighed in on FLGT shares. Weiss Ratings upgraded Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. Wall Street Zen upgraded shares of Fulgent Genetics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. Finally, Piper Sandler increased their target price on Fulgent Genetics from $15.00 to $19.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 4th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $27.50.

Insider Activity at Fulgent Genetics

In other Fulgent Genetics news, COO Jian Xie sold 2,127 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $19.66, for a total transaction of $41,816.82. Following the completion of the sale, the chief operating officer owned 359,924 shares of the company’s stock, valued at approximately $7,076,105.84. This represents a 0.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Hanlin Gao sold 1,673 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $19.66, for a total value of $32,891.18. Following the sale, the insider owned 986,117 shares of the company’s stock, valued at approximately $19,387,060.22. The trade was a 0.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders have sold 5,932 shares of company stock worth $117,156. 36.18% of the stock is owned by corporate insiders.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc is a technology-driven clinical diagnostics company that develops and performs genetic testing. Its testing platform uses next-generation sequencing and other molecular technologies to analyze DNA and support the diagnosis, screening and management of inherited and acquired diseases.

The company offers a range of tests, including panels for hereditary cancer, reproductive health and inherited disorders, as well as tumor profiling and other specialized clinical testing services.